News
Novartis Pharmaceuticals Canada Inc. (Novartis) is pleased to announce that, as of July 2, 2025, Pluvicto® (lutetium (177Lu) vipivotide tetraxetan injection) is publicly reimbursed in Quebec for ...
The global Radioligand Therapy (RLT) market is poised to reach US$13 billion by 2030, expanding at a ~5% CAGR over the ...
Lantheus Holdings offers a compelling bull case, with PYLARIFY and DEFINITY driving valuation and strong growth prospects.
The firm hopes to overcome common dose-limiting toxicities with its PSMA-targeted radiotherapy while boosting potency versus competitors.
Broker UBS believes the three-year rout of ASX healthcare stocks is near an end and it has promoted Cochlear and Resmed to favourite stocks.
JPM's strong NII outlook, NVS's blockbuster pipeline, and T's wireless momentum anchor today's top analyst picks.
Common isotopes include lutetium-177, actinium-225, gallium-68 (diagnostic), fluorine-18, and radium-223. The therapy combines isotopic radiance with molecular targeting-e.g., PSMA in prostate cancer ...
Illuccix® (kit for the preparation of gallium-68 ( 68 Ga) gozetotide injection), Telix's first generation PSMA-PET imaging ...
16d
Zacks Investment Research on MSNAre You a Value Investor? This 1 Stock Could Be the Perfect PickIt doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ...
Northwell’s Phelps Hospital is the first and only medical facility in New York State between the Bronx and Albany to offer Pluvicto, a groundbreaking treatment for men with advanced prostate cancer.
The Trump administration is weighing measures that would make it more expensive for pharmaceutical companies to conduct ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results